Targeted Therapies

  • Author: Gail Wilkes, RNC, ANP-BC, MS, AOCN® (More Info)
  • Section Editor: Marlene SanFilippo, MSN, ARNP, FNP-C, AOCNP®
  • Editors In Chief: Dawn Camp-Sorrell, MSN, FNP, AOCN®; Rebecca Hawkins, MSN, ANP, AOCN®, ACHPN
  • Last Reviewed: 5/26/17 (What's New)

Summary

  • Blocking the PARP enzyme halts DNA repair, leading to cell death (Figure 8)
  • Niraparib (Table 44), olaparib (Table 45), and rucaparib (Table 46) are approved PARP inhibitor for patients with advanced ovarian cancer
  • A key nursing measure is counseling patients on the management of fatigue since a common side effect is anemia

Action required